Yingmai Medical Enters Strategic Partnership with Mingchen Bio to Advance Cardiovascular Smart Imaging

Recently, Enlight Medical Limited (hereinafter referred to as "Enlight Medical") and Shenzhen Mingchen Biotechnology Co., Ltd. (hereinafter referred to as "Mingchen Biotechnology") jointly signed a strategic cooperation agreement to co-develop an integrated cardiovascular diagnosis and treatment system based on medical ultrasound, medical imaging, advanced materials, and intelligent image processing technologies. The two parties will engage in comprehensive and in-depth cooperation in areas such as technology sharing, product development, and market access, aiming to revolutionize current interventional cardiovascular diagnosis and treatment methods and significantly improve the survival rate and quality of life for patients with cardiovascular diseases.

Cardiovascular diseases are the leading cause of morbidity and mortality worldwide, with their incidence continuing to grow explosively. The persistently high mortality rate of cardiovascular diseases is fundamentally due to the mismatch between imaging technology and treatment techniques. Imaging navigation technology acts as the eyes, guiding therapeutic devices to reach target areas efficiently and accurately for complete and effective treatment. The interventional ultrasound imaging equipment developed through this collaboration will integrate with Enlight Medical's range of therapeutic devices and instruments to form a comprehensive diagnosis and treatment solution. This breakthrough overcomes the limitations of traditional imaging equipment by enabling real-time navigation, full visualization of any cardiac region, and precise positioning, establishing itself as a pioneer in the field of cardiovascular diagnosis and treatment.

In recent years, international giants from different fields such as Philips, GE, and Medtronic have made imaging-based intelligent healthcare a key entry point, deeply expanding into the cardiovascular field. This indicates that the era of digital transformation in the medical device industry is approaching. Enlight Medical and Shenzhen Mingchen Biotechnology Co., Ltd.'s groundbreaking smart imaging navigation technology, detection pathways, and real-time anatomical positioning integrate imaging and treatment into one system, which will be indispensable in the future interventional diagnosis and treatment field. The strategic cooperation between Enlight Medical and Shenzhen Mingchen Biotechnology Co., Ltd. will accelerate innovation in cardiovascular interventional therapies, with the potential to achieve revolutionary breakthroughs in integrated imaging and treatment, bringing new hope for curing patients with cardiovascular diseases. At the same time, leveraging their leading technological advantages, they aim to establish authority in the field of ultrasound-based intelligent cardiovascular disease diagnosis and treatment.

Dr. Ruilin Zhao, CEO of Enlight Medical, said

"We are very pleased to reach this strategic cooperation. Enlight Medical will deepen its collaboration with Shenzhen Mingchen Biotechnology Co., Ltd., leveraging the strengths of each in their respective fields to create a synergistic effect where one plus one is greater than two. Enlight Medical has always been committed to 'using the power of technology to improve human health and create a better world.' This cooperation marks another solid step toward that goal."

Wang Yi, General Manager of Shenzhen Mingchen Biotechnology Co., Ltd., stated

"Shenzhen Mingchen Biotechnology Co., Ltd. has years of technical accumulation and engineering implementation capabilities in the fields of medical imaging and artificial intelligence. These are highly complementary to Enlight Medical's market insight and clinical integration abilities in the interventional medicine field. The collaboration between the two parties will help accelerate our layout in the interventional medicine sector and strengthen our advantages in specialized imaging."

Editor: Pea Shooter

Disclaimer: This article is a reprint from PharmNet. The images and text are the property of the original author, and the purpose of the reprint is to convey more information. It does not represent the views of this platform. If there are any issues regarding content, copyright, or other problems, please leave a message on this platform, and we will address it promptly.